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a,-Adrenergic receptors in calf retina membranes can be specifically labeled with the tritiated agonist p-azidopH]cloni- 
dine. Saturation binding in the dark occurs with high affinity (I .3 + 0.3 nM) to a single class of sites (1 I22 + 67 fmol/mg 
protein). Irradiation of the membrane-bound radioligand results in the labeling of a peptide band with an apparent size 
of 65 kDa and a characteristic pharmacological profile for an a,-adrenergic receptor. The carbohydrate moieties of the 
cc,-receptor are characterized by lectin affinity chromatography and glycosidase treatment. The Nonidet P-40solubilized, 
p-azidorH]clonidine-labeled receptors are completely retained by Con A- as well as WGA-Sepharose columns. Neurami- 
nidase, cc-mannosidase and TFMS do not affect the electrophoretic mobility of the receptor on SDS-PAGE whereas endo- 
glycosidase F reduces the apparent size to 45 kDa. 
a,-Adrenergic receptor; p-AzidorHlclonidine; Lectin affinity chromatography; Glycosidase; (Calf retina) 
1. INTRODUCTION 
&2-Adrenergic receptors are located at both pre- 
and postjunctional sites in the central nervous 
system and peripheral organs, as well as non- 
innervated tissues such as blood platelets [I]. 
Species and tissue differences of these receptors 
have already been documented with respect to their 
ligand-binding properties and their ability to pro- 
duce different responses at the membrane level [2]. 
Photoaffinity labeling could constitute a powerful 
tool for the investigation of possible differences in 
the molecular properties of these receptors, since 
they allow apparent M, determinations by SDS- 
PAGE. 
[3H]PAZ-labeled cuz-adrenergic receptors in calf 
retina membranes by both lectin-Sepharose affini- 
ty chromatography and endo- and exoglycosidase 
treatments. The vertebrate retina is developed em- 
bryologically from the brain and offers a conve- 
nient model system for investigation of the 
physiology and biochemistry of specific neuronal 
systems [3]. A considerable advantage of this 
system also resides in the high initial az-receptor 
concentration, the preponderance of high-affinity 
sites for the agonist [3H]PAZ (about 80% of the 
total population), so that no purification step is re- 
quired prior to photoaffinity labeling [4]. 
Here, we characterise the glycoprotein nature of 2. MATERIALS AND METHODS 
Correspondence address: A. Convents, Department of Protein 
Chemistry, lnstituut voor Molekulaire Biologie, Vrije Univer- 
siteit Brussel, Brussels, Belgium 
Abbreviations: [3H]PAZ, p-azido[3H]clonidine; PMSF, 
phenylmethylsulfonyl fluoride; Con A, concanavalin A; WGA, 
wheat germ agglutinin; SDS-PAGE, SDS-polyacrylamide gel 
electrophoresis; TFMS, trifluoromethanesulfonic acid 
2.1. Materials and membrane preparation 
[3H]PAZ (41 Ci/mmol) and endoglycosidase F were supplied 
by New England Nuclear. Neuraminidase (from Clostridium 
perfringens type X) and a-mannosidase were from Sigma. 
PD.10 columns and Sepharose CL 4B were obtained from 
Pharmacia. All other materials were from sources described in 
[41. 
Calf eyes were obtained from a local slaughterhouse and 
membranes were prepared as in [4]. 
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2.2. ?H]PAZ binding 2.5.2. Endoglycosidase F treatment 
Radioligand binding was performed essentially as described 
[4]. Briefly, 50~1 [3H]PAZ (0.1-10 nM) and 5081 buffer A 
[50 mM Tris-HCl (pH 7.5), 10 mM MgCls, 1 mM EGTA, 
1OOpM PMSF] or phentolamine (1OpM) were added in dim 
light to a 400 ,xI membrane suspension (0.25-0.5 mg/ml) in buf- 
fer A. After 90 min incubation at 25”C, the samples were 
filtered, washed and assessed for radioactivity as in [4]. 
[sH]PAZ-labeled membranes were solubilized in 100 mM 
sodium phosphate (pH 6.1), 50 mM EDTA, 0.8% Nonidet 
P-40, 0.1% SDS as described in section 2.4. The soluble frac- 
tion (1 mg protein/ml) was incubated with 10 U/ml (final con- 
centration) endoglycosidase F in a total volume of 100 pl for 5 h 
at 37°C. The samples were then desalted on a PD-10 column to 
exchange the buffer with an aqueous solution of 0.01% SDS, 
and lyophilized overnight prior to SDS-PAGE. 
2.3. Photoaffinity labeling 
Calf retina membranes (0.2-0.3 mg/ml) in buffer A were in- 
cubated in dim light with 4 nM [‘H]PAZ for 90 min at 25°C in 
a final volume of 10 ml. 0.1 ml of 50 mM reduced glutathione 
was then added to the samples as a scavenger. The samples were 
transferred into plastic petri dishes (10 cm diameter) and ir- 
radiated for 10 min with ultraviolet light (254 nm). The mem- 
branes were subsequently washed three times by centrifugation 
at 39000 x g for 20 min and resuspended in fresh buffer A, 
prior to further treatment. 
2.5.3. TFMS treatment 
The method of Edge et al. [8] was employed with some minor 
modifications described by El Battari et al. [9]. 
2.6. SDS-PAGE 
SDS-PAGE was performed according to Laemmli [lo] using 
10% acrylamide slab gels. Following electrophoresis, the gels 
were prepared for fluorography using Enlightning (New 
England Nuclear) according to the manufacturer’s instructions. 
2.4. Lectin affinity chromatography 
Con A was prepared according to Van Driessche et al. [5] and 
stored in 60% (NH&Sob. WGA was purified according to 
Block and Burger [6]. 
3. RESULTS AND DISCUSSION 
The lectins were coupled to Sepharose CL 4B as described by 
Jacobs and Cuatrecasas [7]. Prior to use, lectin columns with 
bed volumes of about 10 ml were extensively washed with 
equilibration buffer [lo mM Tris-HCl (pH 7.4), 0.2% Nonidet 
P-40, 145 mM NaCl, 2 mM MgClz, 2 mM CaClz and the 
following protease inhibitors: 100pM PMSF, 100pM benz- 
amidine, 5 gg/ml pepstatin and 5 pg/ml leupeptin]. [3H]PAZ- 
labeled membranes were solubilized in Nonidet P-40 buffer 
[0.8% Nonidet P-40, 10 mM Tris-HCl (pH 7.4) 145 mM NaCl 
and the above protease inhibitors] for 1 h with constant stirring 
at room temperature. The preparation was then centrifuged at 
48000 x g for 30 min. After application of the solubilized 
membranes, the lectin columns were slowly eluted with 
equilibration buffer and the radioactivity content of the col- 
lected fractions was assayed by scintillation counting. When 
their radioactivity content had returned to the baseline, the col- 
umns were subsequently eluted with equilibration buffer con- 
taining 0.3 M m-methyl-D-mannopyranoside (for Con A 
columns) or 0.3 M N-acetylglucosamine (for WGA columns). 
Flow-through fractions and specifically eluted fractions were 
pooled, desalted with a PD-10 column and lyophilized over- 
night. 
The specific binding of [3H]PAZ to calf retina 
membranes is reversible in the dark and occurs to 
one class of non-cooperative sites. The Scatchard 
plot of [3H]PAZ saturation binding data is linear 
(r = 0.96, nH = 1.02) with an equilibrium dissocia- 
tion constant of 1.3 f 0.3 nM (n = 3) and a total 
number of binding sites (Bmax) of 1122 f 67 fmol/ 
mg protein (fig. 1). The equilibrium dissociation 
constant is in good agreement with the value for 
unlabeled clonidine for the high-affinity sites, and 
the number of sites corresponds to the amount of 
sites for the radiolabeled agonist [3H]UK 14304 
2.5. Deglycosylation procedure 
2.5.1. Exoglycosidase treatment 
[3H]PAZ-labeled membranes were suspended in 100 mM (pH 
5.0) or 50 mM (pH 4.5) sodium acetate buffer supplemented 
with protease inhibitors for neuraminidase and cu-mannosidase 
treatment, respectively. The reaction was started by addition of 
0.5-l U/ml neuraminidase or 3-4 U/ml a-mannosidase (final 
concentrations) for 6 h at 37°C. The reactions were stopped by 
centrifugation and subsequent suspension in SDS-PAGE sam- 
ple buffer [50 mM Tris-HCl (pH 8.8) 10% SDS, 5 mM EDTA, 
10 mM DTT, 10% glycerol]. 
0 .5 i 
BOUND ( pmol / mg protein) 
Fig.1. Scatchard plot of [‘H]PAZ saturation binding to calf 
retina membranes. Calf retina membranes were incubated in the 
dark with increasing concentrations of [3H]PAZ (0.1-10 nM). 
Data shown represent specific binding as described in section 2 
(duplicate determinations). 
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Fig.2. Autoradiograph of the pharmacological specificity of 
[3H]PAZ photoaffinity labeling. Membranes were incubated 
with 4 nM [3H]PAZ in the presence of 1 pM prazosin, 10 ,uM 
idazoxan, 10/M phentolamine, 1OpM propranolol, or in the 
absence of competitor (control). Photolysis, SDS-PAGE and 
autoradiography were performed as described in section 2. 
(1.3 pmol/mg protein) in this tissue [4]. The 
equilibrium dissociation constant for [3H]PAZ is 
one to two orders of magnitude lower than the 
recently reported values for the photoreactive an- 
tagonists [3H]SKF-102229 and lz51-rau-AzPC and 
the irreversible antagonist [3H]phenoxybenzamine 
[l l-131. 
Irradiation of [3H]PAZ (4 nM)-labeled calf 
retina membranes results in covalent binding of the 
radioligand. The photolyzed membranes can be 
solubilized and subjected to SDS-PAGE. Whereas 
successful affinity labeling by antagonists often re- 
quires a preliminary partial purification step for 
cuz-adrenergic receptors [l l-131, this step is not 
necessary for [3H]PAZ labeling in calf retina mem- 
branes. Indeed, the autoradiogram of the gel 
shows one broad peptide band with an apparent 
molecular mass 64 kDa (fig.2). The binding 
characteristics of the 64 kDa peptide correspond to 
those of an cuz-adrenergic receptor. t3H]PAZ label- 
ing is inhibited by the selective cuz-adrenergic an- 
tagonist idazoxan (10 PM) as well as by the 
non-cu-adrenergic subtype selective antagonist 
phentolamine (10 PM), but not by the ,&adrenergic 
antagonist propanolol(l0 ,uM) and the aul-adrener- 
gic antagonist prazosin (1 ,uM) (fig.2). In addition, 
Fig.3. Stereoselective inhibition of 13H]PAZ incorporation by 
epinephrine. Membranes were incubated with [3H]PAZ in the 
presence of 1 pM (- )-epinephrine or 1 pM (+ )-epinephrine 
and treated further as in fig.2. 
labeling of this peptide is inhibited in a stereoselec- 
tive manner by the agonist epinephrine (fig.3). 
The [3H]PAZ-labeled calf retina Lu2-receptors 
display similar molecular sizes to those recently 
described for photoreactive antagonists in, for ex- 
ample, human platelets or porcine brain [l 1,121. 
The fact that antagonist- and agonist-labeled 
receptors show comparable bands on SDS-PAGE, 
indicates that the apparent molecular size of the 
functional G-coupled receptors is the same, or at 
least very similar to that of the non-coupled recep- 
tors [ 141. Despite the similarities in molecular size, 
the pharmacological binding properties of 
az-adrenergic receptors have been reported to be 
heterogeneous [2]. For instance, cuz-adrenergic 
receptors in calf retina [4] display an antagonist 
potency order (idazoxan = phentolamine > 
rauwolscine) which is different from that observed 
in human platelets (rauwolscine = phentolamine 
> RX 781094) [2]. Accordingly, a putative classifi- 
cation of the a2-receptors will have to await the 
comparative characterization of receptor amino 
acid sequences by cloning techniques. 
Sugar moieties on the a2-adrenergic receptor 
were first characterized by investigating their 
retention on immobilized Con A and WGA lectins. 
The affinity-labeled membranes were first solu- 
bilized in 0.8% Nonidet P-40 and subsequently 
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diluted to obtain a final detergent concentration of 
0.2%. This reduction in detergent concentration 
allowed more efficient retention of the [3H]PAZ- 
labeled peptide by the lectin-Sepharose columns. 
As shown in fig.4, both the Con A- (which binds 
specifically to mannose-containing carbohydrates) 
[ 151 and the WGA-Sepharose (which interacts with 
N-acetylglucosamine) [15] columns are able to re- 
tain the total arz-adrenergic receptor population; 
i.e. the 64 kDa peptide is absent in the flow- 
Fig.4. Lectin affinity chromatography of [3H]PAZ-Iabeled 
Luz-adrenergic receptors. Membranes were labeled with 
[‘H]PAZ, solubilized with Nonidet P-40 and applied onto Con 
A-Sepharose and WGA-Sepharose columns as described in sec- 
tion 2. After the radioactivity of the flow-through had returned 
to the baseline level, the columns were eked with the com- 
plementary sugars. The how-through and specifically efuted 
fractions were pooled, desalted, lyophilized and subjected to 
SDS-PAGE. The autoradiograms of these gels are shown in the 
insets. Con A chromatography: A, fractions 1-8; B, fractions 
16-25. WGA chromatography: C, fractions l-8; D, fractions 
22-30. 
through fractions. Subsequent elution of the col- 
umns with 0.3 M cu-methyl-D-mannopyranoside 
(for Con A-Sepharose) or 0.3 M N-acetylglucos- 
amine (WGA-Sepharose) results in the elution of 
the absorbed 64 kDa peptide (fig.4). 
Further information on the glycoprotein nature 
of the a*-adrenergic receptors was obtained by in- 
vestigating the effect of exoglycosidases on their 
apparent molecular mass. Following L3H]PAZ 
labefing, membranes were treated with the 
neuraminidase (to hydrolyse terminal sialic acid 
residues) and ~-mannosidase (to hydrolyse ter- 
minal mannose residues) for 6 h as outlined in sec- 
tion 2. Both treatments do not affect the 
electrophoretic mobility of the receptor (fig.5). 
When the incubation time is increased up to 24 h 
there is still no alteration in electrophoretic mobili- 
ty (not shown). These findings, together with the 
results of the lectin affinity chromatography, sug- 
gest that the carbohydrates on these receptors are 
all bisected biantennary complex type chains [15]. 
The lack of effect of neuraminidase is rather unex- 
pected, since complex type carbohydrates usually 
contain terminal sialic acids and since the removal 
of even a single sialic acid residue already produces 
a relatively dramatic change in the electrophoretic 
mobility of glycoproteins [ 151, The apparent 
Fig.5. Exoglycosidase treatment of [3H]PAZ-labeled az-adre- 
nergic receptors. Membranes were labeled with [jH]PAZ, 
washed with sodium acetate buffer and subsequently incubated 
with buffer only (lane A), 0.5-l U/m1 neuraminidase (lane B) 
or 3-4 U/ml a-mannosidase (lane C) for 5 h and the reaction 
was stopped by centrifugation. 
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-94 KO 
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Fig.6. Effect of endoglycosidase F and TFMS on [‘HIPAZ- 
labeled cuz-adrenergic receptors. Membranes were labeled with 
[3H]PAZ and solubilized with SDS/Nonidet P 40. The soluble 
fraction was incubated in buffer only (lane A), in the presence 
of 10 U/ml endoglycosidase F for 5 h (lane B), or lyophilized 
overnight and incubated with 2: 1 (v/v) TFMS/anisole (lane C) 
as described by Edge et al. [8]. 
absence of terminal sialic acids might be due to a 
single interruption in the highly ordered enzymatic 
reactions required to produce a complex oligosac- 
charide chain with terminal sialic acid residues. 
Another possibility is that sialic acid is actually 
present, but is not susceptible to neuraminidase 
hydrolysis. For example, sialyl-N-acetylgalactos- 
amine linkages are relatively resistant to 
neuraminidase [ 151. 
[3H]PAZ-labeled membranes were also treated 
respectively with endoglycosidase F (to remove 
both complex and high-mannose type carbo- 
hydrate chains which are N-linked to asparagine) 
[ 151 and TFMS (to remove the chains which are O- 
linked to serine or threonine) [8]. As depicted in 
fig.6, endoglycosidase F treatment produces a 
dramatic decrease in the apparent molecular mass 
of the a*-adrenergic receptor, whereas TFMS has 
no perceptible effect. The final product of endo- 
glycosidase F treatment is a 45 kDa peptide (fig.6). 
Prolongation of the incubation times does not fur- 
ther affect the electrophoretic mobility of the 
receptor on SDS-PAGE. This value is similar to 
that expected for the protein backbone in the 
human platelet receptor on the basis of its DNA se- 
quence [16]. Further work has to be elaborated to 
determine if the carbohydrate chains on the 
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cY2-receptors are necessary for binding of the hor- 
mone, transmembrane signalling or mobilization 
of second messengers. 
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